$PMCB
PharmaCyte Biotech, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Las Vegas, NV
PMCB chart
What traders are saying about $PMCB
Latest postsPharmaCyte Biotech, Inc. news
- PharmaCyte Biotech, Inc. Estimates – NASDAQ:PMCB
TradingView ·
- Form PRE 14A PharmaCyte Biotech Inc For: 24 October By Investing.com
Investing.com Canada ·
PharmaCyte Biotech, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net income | -$19.4M | $30.7M | $333,763 | -$4.3M |
| Diluted EPS | $-2.77 | $3.19 | $-1.80 | $-0.22 |
| Total assets (year end) | $55.9M | $43.8M | $71.4M | $78.0M |
| Cash and equivalents (year end) | $20.2M | $16.4M | $61.2M | – |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 8-KFORM 8-K
- 10-QFORM 10-Q FOR JUL 2026
- 10-KFORM 10-K FOR APRIL 2026
- 8-KFORM 8-K
- 10-QFORM 10-Q FOR JAN 2026
- DEF 14ADEFINITIVE PROXY STATEMENT
- 10-QFORM 10-Q FOR OCT 2025
- 8-KFORM 8-K
- 8-K/A8-K/A
- 8-KFORM 8-K
- DEF 14ADEFINITIVE PROXY STATEMENT
- 10-QFORM 10-Q FOR JUL 2025
About PharmaCyte Biotech, Inc.
- Ticker
- PMCB (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Las Vegas, NV
- Incorporated in
- NV
- Fiscal year end
- April 30
- SEC CIK
- 1157075
- Former names
- NUVILEX, INC., EFOODSAFETY COM INC
Frequently asked questions
What exchange is PharmaCyte Biotech, Inc. listed on?
PharmaCyte Biotech, Inc. trades on the Nasdaq under the ticker symbol PMCB.
What industry is PharmaCyte Biotech, Inc. in?
PharmaCyte Biotech, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is PharmaCyte Biotech, Inc. headquartered?
PharmaCyte Biotech, Inc.'s business address on file with the SEC is in Las Vegas, NV.
When does PharmaCyte Biotech, Inc.'s fiscal year end?
PharmaCyte Biotech, Inc.'s fiscal year ends on April 30.
How much revenue did PharmaCyte Biotech, Inc. report?
PharmaCyte Biotech, Inc. reported $0 in revenue for calendar year 2025, according to its SEC filings.